Newron Pharmaceuticals Spa. 

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing treatments for disorders affecting the central and peripheral nervous systems, as well as pain conditions. Operating in both Italy and the United States, the company's portfolio includes Xadago (safinamide), an approved therapy for Parkinson's disease, which is also under investigation for levodopa-induced dyskinesia. Additionally, Newron is developing Evenamide for schizophrenia and its treatment-resistant form, and Ralfinamide for specific orphan indications in neuropathic pain. Established in 1999, Newron Pharmaceuticals S.p.A. maintains its headquarters in Bresso, Italy.